The impact of genetic variants of PEAR1 on platelet response and outcome in patients with CAD undergoing PCI treated with contempory P2Y12 inhibitors has insufficiently been studied (Xiang et al., 2013). The gene discussed is PEAR1; the disease is coronary artery disorder.